| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 26 | 2024 | 3707 | 1.730 |
Why?
|
| Camptothecin | 7 | 2020 | 540 | 1.310 |
Why?
|
| Bevacizumab | 3 | 2020 | 967 | 0.760 |
Why?
|
| Metastasectomy | 3 | 2020 | 209 | 0.730 |
Why?
|
| Aluminum Silicates | 1 | 2014 | 16 | 0.480 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2015 | 894 | 0.430 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 7 | 2023 | 1402 | 0.420 |
Why?
|
| Diarrhea | 2 | 2023 | 716 | 0.410 |
Why?
|
| Colonic Neoplasms | 3 | 2023 | 1435 | 0.370 |
Why?
|
| Biomarkers, Tumor | 12 | 2024 | 10708 | 0.360 |
Why?
|
| Circulating Tumor DNA | 3 | 2023 | 274 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 16689 | 0.330 |
Why?
|
| Organoplatinum Compounds | 5 | 2020 | 704 | 0.320 |
Why?
|
| Liver Neoplasms | 7 | 2024 | 4821 | 0.310 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2016 | 1336 | 0.280 |
Why?
|
| CpG Islands | 5 | 2020 | 671 | 0.270 |
Why?
|
| Mutation | 14 | 2023 | 15912 | 0.270 |
Why?
|
| Cetuximab | 3 | 2016 | 474 | 0.260 |
Why?
|
| Microsatellite Instability | 4 | 2023 | 408 | 0.260 |
Why?
|
| Aged | 28 | 2024 | 73333 | 0.220 |
Why?
|
| Neoplasms | 9 | 2023 | 15927 | 0.220 |
Why?
|
| Middle Aged | 31 | 2024 | 90352 | 0.210 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 334 | 0.210 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2019 | 637 | 0.200 |
Why?
|
| Adenocarcinoma | 4 | 2024 | 7914 | 0.190 |
Why?
|
| Appendiceal Neoplasms | 1 | 2024 | 251 | 0.190 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2024 | 340 | 0.190 |
Why?
|
| Splenic Infarction | 1 | 2020 | 13 | 0.180 |
Why?
|
| Young Adult | 12 | 2021 | 22251 | 0.180 |
Why?
|
| Hypersplenism | 1 | 2020 | 23 | 0.180 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 30998 | 0.180 |
Why?
|
| Adult | 23 | 2024 | 82040 | 0.170 |
Why?
|
| Male | 31 | 2024 | 128315 | 0.170 |
Why?
|
| Fluorouracil | 3 | 2020 | 1990 | 0.170 |
Why?
|
| Aspirin | 1 | 2022 | 375 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2019 | 5408 | 0.170 |
Why?
|
| Leucovorin | 1 | 2020 | 345 | 0.170 |
Why?
|
| Fertility Preservation | 1 | 2021 | 151 | 0.160 |
Why?
|
| Female | 32 | 2024 | 148940 | 0.160 |
Why?
|
| Survival Rate | 8 | 2020 | 12541 | 0.160 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 3530 | 0.160 |
Why?
|
| DNA Mutational Analysis | 4 | 2018 | 2357 | 0.160 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2019 | 180 | 0.150 |
Why?
|
| Genomics | 2 | 2019 | 2835 | 0.150 |
Why?
|
| Humans | 40 | 2024 | 270740 | 0.150 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2017 | 80 | 0.140 |
Why?
|
| DNA Methylation | 5 | 2019 | 2765 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 533 | 0.140 |
Why?
|
| Sulfonamides | 2 | 2016 | 1933 | 0.130 |
Why?
|
| Albumins | 1 | 2018 | 262 | 0.130 |
Why?
|
| Retrospective Studies | 13 | 2024 | 39890 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 15218 | 0.130 |
Why?
|
| Vimentin | 1 | 2016 | 252 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 1388 | 0.130 |
Why?
|
| Patient Selection | 2 | 2020 | 2025 | 0.120 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 605 | 0.120 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2017 | 232 | 0.120 |
Why?
|
| ErbB Receptors | 3 | 2023 | 2375 | 0.120 |
Why?
|
| Intestine, Small | 1 | 2018 | 522 | 0.120 |
Why?
|
| Liver | 1 | 2024 | 3086 | 0.120 |
Why?
|
| Rectal Neoplasms | 1 | 2022 | 1240 | 0.110 |
Why?
|
| Gonadal Disorders | 1 | 2013 | 8 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 9042 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 861 | 0.110 |
Why?
|
| Placebos | 1 | 2014 | 442 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2023 | 1840 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 3 | 2022 | 4481 | 0.110 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 14617 | 0.110 |
Why?
|
| DNA, Neoplasm | 2 | 2015 | 1958 | 0.100 |
Why?
|
| Neoplasm Metastasis | 4 | 2019 | 5315 | 0.100 |
Why?
|
| Prognosis | 6 | 2020 | 22505 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 454 | 0.100 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 12033 | 0.100 |
Why?
|
| Peritoneal Neoplasms | 2 | 2019 | 859 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2017 | 1192 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 2359 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 3409 | 0.100 |
Why?
|
| Indoles | 1 | 2016 | 1028 | 0.090 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 617 | 0.090 |
Why?
|
| Ovariectomy | 1 | 2012 | 371 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2018 | 2101 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 379 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 5231 | 0.080 |
Why?
|
| Physicians | 1 | 2017 | 854 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 4372 | 0.080 |
Why?
|
| DNA | 1 | 2017 | 3050 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2014 | 2580 | 0.080 |
Why?
|
| Metformin | 1 | 2012 | 393 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 1586 | 0.070 |
Why?
|
| Treatment Outcome | 6 | 2021 | 33737 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 599 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 1269 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 4961 | 0.070 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 10265 | 0.070 |
Why?
|
| ras Proteins | 3 | 2019 | 804 | 0.070 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2021 | 529 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2023 | 2353 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2021 | 1437 | 0.060 |
Why?
|
| Capecitabine | 2 | 2016 | 390 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 5776 | 0.060 |
Why?
|
| Genes, erbB | 1 | 2023 | 27 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2024 | 231 | 0.060 |
Why?
|
| CA-19-9 Antigen | 1 | 2024 | 155 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2024 | 229 | 0.050 |
Why?
|
| Organ Size | 1 | 2024 | 692 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 3658 | 0.050 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2022 | 59 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2015 | 3669 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 1710 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2020 | 3216 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1412 | 0.050 |
Why?
|
| Adolescent | 5 | 2021 | 32767 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2024 | 318 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3035 | 0.050 |
Why?
|
| Nausea | 1 | 2023 | 539 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 382 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2022 | 627 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2022 | 318 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2021 | 149 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 1267 | 0.040 |
Why?
|
| Palliative Care | 1 | 2012 | 2178 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 6256 | 0.040 |
Why?
|
| Pyridones | 1 | 2022 | 360 | 0.040 |
Why?
|
| Safety | 1 | 2021 | 460 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2020 | 229 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 4895 | 0.040 |
Why?
|
| Documentation | 1 | 2021 | 213 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 492 | 0.040 |
Why?
|
| Melanoma | 1 | 2016 | 5595 | 0.040 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 14012 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 275 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2023 | 1060 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 657 | 0.040 |
Why?
|
| Fertility | 1 | 2021 | 336 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 672 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3917 | 0.040 |
Why?
|
| Spleen | 1 | 2020 | 726 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 6509 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 117 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2017 | 59 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 1137 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 16215 | 0.030 |
Why?
|
| Genetics, Medical | 1 | 2017 | 141 | 0.030 |
Why?
|
| Cell-Free System | 1 | 2016 | 175 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 4963 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2024 | 4019 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 4795 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 1097 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2016 | 85 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 1655 | 0.030 |
Why?
|
| Disease Progression | 2 | 2019 | 6867 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 896 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 3345 | 0.030 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2015 | 175 | 0.030 |
Why?
|
| Genes, erbB-1 | 1 | 2015 | 104 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2016 | 9292 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 625 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2022 | 2232 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2828 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2015 | 2617 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2015 | 255 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 377 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 1826 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 2457 | 0.030 |
Why?
|
| Clone Cells | 1 | 2015 | 591 | 0.030 |
Why?
|
| Recurrence | 2 | 2013 | 4878 | 0.030 |
Why?
|
| Exons | 1 | 2017 | 1383 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2023 | 2651 | 0.030 |
Why?
|
| Indazoles | 1 | 2015 | 310 | 0.030 |
Why?
|
| Proteolysis | 1 | 2015 | 380 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 618 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4492 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 875 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 1441 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 917 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2024 | 9470 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1322 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2017 | 13414 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 14849 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 1608 | 0.020 |
Why?
|
| Organosilicon Compounds | 1 | 2010 | 3 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2904 | 0.020 |
Why?
|
| Azacitidine | 1 | 2016 | 1218 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2017 | 1207 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 13006 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2399 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 2115 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2017 | 1465 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2014 | 1389 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 9039 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2014 | 1567 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 729 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 7783 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 1340 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 5162 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 4000 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 5101 | 0.020 |
Why?
|
| Risk Factors | 2 | 2013 | 17888 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 3404 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 5923 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 4328 | 0.010 |
Why?
|
| Texas | 1 | 2015 | 6449 | 0.010 |
Why?
|
| Animals | 2 | 2018 | 61956 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 5056 | 0.010 |
Why?
|
| Child | 1 | 2020 | 30559 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 35600 | 0.010 |
Why?
|